hpski

American Oriental Bioengineering Stirs Up Controversy

The intricacies Chinese herbal medicine is outside my knowledge base, however US based companies of similar profile usually don't get this much attention. It' been my observation that pharma type companies look at secondary offerings as a way to either continue drug development and/or to acquire a later stage med, or a company in possession of such. It appears that AOB is gearing up for one or more acquisitions. From a marketing perspective, the U.S. population in general has been spending more $$ on alternative medicine than ever before - if AOB uses the proceeds to enter the US market, its valuation may be bid up considerably. I am presently not a buyer of this stock, given the Barron's article, merged with the current controversy surrounding quality control of Chinese imports.